Breathing fire into targeted therapies at ASH23

In our latest Preview from the American Society of Hematology, we’re using the dragon’s…

November 30, 2023

Pointing the IO way

Eight key areas to watch out for at SITC 2023!

October 27, 2023

Process is power

Dawn of a new IO era at ESMO23?

October 23, 2023

How to Knock Out Cancer’s Backup Plan

Searching for well tolerated combinations in the KRAS niche

October 13, 2023

The Next Frontier

From small acorns, so oak trees grow

October 12, 2023

What to watch out for at TARGETS23 – Part 2

What to watch out for in DDR, epigenetic therapies, and other hot topics

October 11, 2023

Ever Decreasing Circles

From epigenetics to SHP2, a look at various upcoming presentations this month

October 5, 2023

ESMO23 Preview 1 – Hype over Hope?

Parsing cancer research hype at ESMO23

September 27, 2023

Early stage oncology data of interest in TARGETS23 preview

A look at some hot topics from the TARGETS/TRIPLE meeting in Boston

September 20, 2023

What science tells us about future directions in lung cancer

What we can learn from scientific talks at WCLC in order to improve clinical development

September 13, 2023

Kicking KRAS to the kerb

Review of new KRAS inhibitor studies including G12C and G12D

September 11, 2023

New Developments in Targeting Pancreatic Cancer

Important new preclinical data sets the scene for PDAC

August 30, 2023

A flurry of new biomarkers are coming to the fore

How exploratory new biomarkers are paving the way

August 14, 2023

What’s hot in lung cancer?

Preview - Wwat to watch for at WCLC23

July 27, 2023

An under-rated gem at ASCO23

Tackling intractable cancers with a novel and creative approach to the problem

June 8, 2023

Intriguing progress on the KRAS front

Novel KRAS developments to watch out for

June 1, 2023

Heading to the stars in RAS driven cancers

A next generation category of KRAS inhibitors are emerging - W2W4

May 10, 2023

AACR23 Insights on gems from the poster halls – Part 1

Where we explain what to look for in 10 posters presented at AACR23

April 25, 2023

AACR23 – New is not necessarily better

Orlando – At AACR23 the old adage of “be the first, or be the best” is well and truly…

April 18, 2023

AACR23 – is the Florida sun shining on KRAS?

Initial learnings on KRAS presentations at AACR23

April 17, 2023
The key to success in TPD

AACR23 Preview 8 – Keys to success in TPD

W2W4 on the TPD front

April 14, 2023

AACR23 Preview 7 – Surfeit of riches

From one compound to many competitors following in their wake!

April 4, 2023

AACR23 Preview 6 – Taking a closer look at KRAS Part 1

The ever evolving selective KRAS inhibitor & degrader space

March 29, 2023

AACR23 Preview 3 – Emerging agents with a different mechanism of action

As we continue our new products journey evaluating early stage agents in development with data at…

March 16, 2023

AACR23 Preview 1 – What to watch for

Half a dozen key early areas to watch out for

March 13, 2023

Will targeting KRAS G12D prove more successful than G12C?

Going beyond the first past the post syndrome...

January 25, 2023

Shining the light

How novel bispecifics might help potentiate the impact of KRAS inhibitors when combined with checkpoint blockade

January 9, 2023

Moving targets

Ten emerging development areas to watch out for in oncology during 2023

January 5, 2023

Caveat emptor

A hard look at the KRYSTAL-7 data presented at ESMO IO

December 7, 2022

Exciting new developments in the KRAS space

What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on…

November 2, 2022

On overcoming resistance to protein degraders

Are there opportunities for combining small molecule inhibitors with protein degraders?

October 19, 2022

Reflections on ESMO22

What really stood out from the oral presentations at ESMO this year?

September 16, 2022

Analysis of the CodeBreak 200 trial in lung cancer

An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors

September 14, 2022

ESMO22 Preview on Targeted Therapies in Developmental Therapeutics

New developments in early stage targeted therapy agents

September 6, 2022

Going beyond sotorasib and adagrasib

On fast followers and novel G12C combinations

August 8, 2022

The road to Damascus is paved with good intentions

Trials and tribulations associated with KRAS plus IO combos

August 8, 2022

Important new oncology developments to watch out for

6 important and encouraging new developments to watch out for

July 29, 2022

Are we overpromising with protein degraders?

Going beyond small molecule inhibitors to degrading various intractable targets

July 19, 2022

What do the Konami code and targeting KRAS have in common?

A rock around the KRAS clock

July 12, 2022

Seeing the wood from the trees in early stage oncology pipelines

Exploring future IO-IO combination strategies and life cycle management

June 16, 2022

A critical review of five different targeted therapy approaches at ASCO

Where five different targeted therapies are put through their paces

June 13, 2022

ASCO22 Highlights from Day 1

When cell therapies and targeted therapies collide

June 4, 2022

Up and coming cell therapy companies to watch out for

What can we learn from a raft of early cell therapy companies with novel or intriguing approaches?

May 24, 2022

Watch to watch out for at ASCO22

Hot or not - 5 early stage trials with different agents and targets

May 5, 2022

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022

AACR22 Part 2 of the RASpalooza

Highlights from the KRAS front with three different company products not named sotorasib or adagrasib

April 13, 2022

An explosion of new opportunities in the expanding KRAS landscape

Going beyond both G12C and G12D to a plethora of new targets and combination approaches

April 10, 2022

Addressing acquired resistance through novel combination strategies

All aboard to hear more about novel targeted therapy combination strategies...

April 8, 2022

Are there challenging times ahead for KRAS inhibitor combinations?

A lion roar or whimper at the prospect of KRASi plus IO trials?

April 5, 2022

Challenges and opportunities with two different onco modalities

The latest on bispecifics and protein degraders

March 10, 2022

AACR22 Preview 1 – Key topics to watch out for

Hot topics to follow at AACR22

March 7, 2022

Sotorasib impresses unexpectedly in pancreatic cancer

Trick or treat? A look at the sotorasib data in PDAC.

February 14, 2022

Learning from what patients tumours are telling us

Cracking the tumour code

February 4, 2022

Doubling down on modest data

A look at some recent phase 2 data in the KRAS niche in the context of the broader landscape

January 27, 2022

Important changes to watch out for in the GI cancer landscape

Preview of what to watch out for at ASCO GI22

January 18, 2022

Oncology trends and directions to watch out for in 2022

What to watch out for in 2022

January 7, 2022

Going beyond the obvious in RAS driven cancers

A dozen early stage biotechs in the RAS/RAF pathway to watch out for

November 29, 2021

New trials and tribulations in drugging KRAS mutations

A number of new developments to consider in the KRAS niche

November 12, 2021

A review of the emerging bispecific landscape

A look at the sheer breadth and depth of bispecific approaches from a myriad of different biotechs

October 27, 2021
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

New directions in drugging KRAS

Where next in the ever expanding KRAS runners and riders?

October 11, 2021

Spotting the wood from the trees

What can we learn from KRASi combinations? Do any stand out?

October 7, 2021

When things fall apart

One of the things that struck me at this year’s ESMO conference was the sheer variety and richness…

September 29, 2021

Spotting the path forward

Developmental Therapeutics is hard, how do companies go about finding a way forward?

September 20, 2021

No, no absolutely not!

A look at the controversial adagrasib data in mCRC at ESMO21

September 20, 2021

Standing out from the crowd in lung cancer

Highlights from WCLC Day 1

September 9, 2021

Novel strategies for addressing an intractable cancer target

A look at some cool science and novel strategies for tackling an intractable target

September 2, 2021

Coming back full circle

Can a genomic signature help select patients more accurately for DDR therapies?

August 26, 2021

WCLC21 Preview of key data to watch out for

What's hot at WCLC21?

August 19, 2021

Sticking it to MYC addicted cancers and other targets

It's time to tackle some intractable targets in oncology and elsewhere...

August 12, 2021

A bridge to a broad and deep oncology pipeline

What are Novartis up to these days with their oncology pipeline and what are they excited about?

July 29, 2021

Shipping the KRAS line

Update on the Novartis SHP2 inhibitor at ASCO21

June 8, 2021

Highlights and lowlights from the ASCO21 data drop

Which abstracts stood out in the initial run through of the data? Includes some hidden gems and surprises!

May 20, 2021

Digging deep on SHP2 and KRAS

New developments on the KRAS and SHP2 front

May 17, 2021

A twist in chemical moeity

A look at the subtleties and nuances under the hood of the Arvinas PROTACs

April 27, 2021

Fifteen AACR21 On Demand Presentations To Watch

Noteworthy AACR21 on-demand presentations.

March 23, 2021

Novel combination strategies to enhance KRAS inhibitors

Combinations will be the future for KRAS inhibitors but which ones and why? Includes some new ideas!

March 16, 2021

The broad and deep protein degradation landscape

Getting to the centre of things with protein degradation

March 9, 2021

What happens when genomics, KRAS, and IO converge in lung cancer?

Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?

February 2, 2021

A critical look at the Amgen sotorasib data in KRAS G12C mutated lung cancers

Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore

February 1, 2021

Parallel lines: opportunities and challenges in GI cancers

Important developments on the GI cancer front to watch out for

January 19, 2021

Bigging up targeted therapies at ASH 2020

W2W4 in targeted therapies at ASH20 - some key early stage areas to focus on

December 4, 2020

Moving On Up

We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat

October 29, 2020

Buildings walls versus building cathedrals

The devil is in the finer details...

October 27, 2020

What can we learn from Mirati’s adagrasib in lung and other cancers?

It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…

October 25, 2020

TRIPLE highlights and lowlights in Developmental Therapeutics

The trials and tribulations of targeted agents in developmental therapeutics

October 25, 2020

New developments in the KRAS landscape

An update on two very different targets in the broader KRAS niche, one of which may have a particularly long lasting impact on the landscape.

October 15, 2020

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020

ESMO20 Preview 1 – Key progress in biomarker development

A look at progress and new developments in cancer biomarker developments

September 9, 2020

Encouraging progress in immunometabolism

Novel approaches to metabolism may have far-reaching effects on anti-cancer therapies

September 1, 2020

A novel way to target KRAS mutant lung cancer

Rare mutations in lung cancer (STK11/KEAP1) could be associated with defects in cancer metabolism - we look how they impact KRAS mutant lung cancer

August 13, 2020

Building up a storm against resistant solid tumours

Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…

August 5, 2020

Controversial developments in pancreatic cancer

What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?

July 30, 2020

A new dawn for epigenetic therapy in oncology

A novel epigenetic target may have far-reaching outcomes for cancer patients

July 23, 2020

Solid tumour winners and losers at ASCO20

Highlights from several solid tumour trials in both early and late stage disease.

June 9, 2020

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020

Postcards from Day 1 of AACR20

Commentary on Day 1 of the AACR20 Virtual Meeting

April 28, 2020

Reflections on new developments in the KRAS niche

Beyond KRAS G12C inhibitors, there are plenty of other related targets to consider including KRAS::SOS1 and SHP2

April 20, 2020

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020

A look at Mirati in the context of the broader KRAS niche

An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche

February 25, 2020

A hidden gem in the KRAS niche

Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?

February 19, 2020

Competition rapidly heats up in the KRAS space!

Overcoming acquired resistance to KRAS inhibitors will be key to success - here's one potential way to do that.

January 20, 2020

The Future of Oncology R&D

Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines

January 6, 2020

Update on the KRAS Runners and Riders

A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.

December 3, 2019

Insights on targeting the oncogene SHP2

How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.

October 30, 2019

New path to market opportunity for Kura in SCCHN

KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib

October 29, 2019

What do we learn from a first look at Mirati’s KRAS G12C inhibitor MRTX849?

Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?

October 28, 2019

Further issues surrounding RAS inhibition in oncology

On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...

October 25, 2019

A novel approach to targeting BRAF and KRAS mutant cancers

How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...

October 23, 2019

Update on Amgen’s KRAS inhibitor in solid tumours

We saw signs of activity from Amgen's KRAS G12C inhibitor in lung cancer at WCLC so it's time to look at what happens in colorectal cancer.

September 28, 2019

Targeting KRAS – Highlights from WCLC 2019

Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…

September 9, 2019

Will bromodomain inhibitors and PROTACs make an impact?

A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC

September 4, 2019

Can a new class of agents therapeutically target the MYC or RAS oncogenes?

How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...

September 3, 2019

Through the window on the MYC oncogene

What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?

August 21, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019

Challenges of targeting KRAS G12C and why Amgen’s AMG 510 may not be a winner

Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche

May 15, 2019

TKIs are still alive and kicking!

Drugging the undruggable with creative approaches to molecule development

January 9, 2019

Journal Club – February 2017

A look at what we can learn from some recently published new papers in the oncology space.

February 9, 2017